Viatris (VTRS) stock
Last close $21.06 on 2026-11-11 (+1.01%) · Sector: Healthcare
Viatris is a global drugmaker formed in 2020 when Mylan merged with Upjohn, a unit of Pfizer. It makes a wide range of medicines, including lower-cost generic versions of well-known drugs and branded products, and earns money by selling them to pharmacies, hospitals, and health systems around the world.
Viatris had about 14.7 billion dollars in revenue over the last 12 months, but it still shows a small loss per share over that span, so its profits are not yet steady. The stock returned 88.0% over the past year versus 11.3% for the S&P 500, and it trades within 0.2% of its 52-week high. Its latest quarter beat earnings expectations and raised the yearly outlook, though revenue came in slightly short. The stock fell the day after 3 of its last 4 earnings reports and rose after only 1.
Key numbers
- Market cap: $24.2B
- Revenue (last 12 months): $14.73B
- Revenue growth: +4.3%
- Gross margin: 35.3%
- Operating margin: 0.0%
- P/S: 1.6
- Debt to equity: 0.85
- Current ratio: 1.55
Quality score
Overall 30/100 · growth 33 · profitability 20 · financial health 38 · value None
Performance and risk
1-year return +88.0% vs S&P 500 +11.2% · volatility 30.9% (S&P 500 13.7%) · largest drop -19.6% · beta 0.64
Stock move the day after earnings
- 2026-02-26: -5.2%
- 2026-05-07: +9.0%
- 2026-08-06: -7.7%
- 2026-11-05: -1.3%
Insider trades (12 months)
Bought $0.0M · sold $1.1M
VTRS stock research · VTRS options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.